Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
AIDS Res Ther ; 21(1): 21, 2024 04 12.
Article in English | MEDLINE | ID: mdl-38609992

ABSTRACT

BACKGROUND: Maintaining people living with HIV (PLWHIV) in clinical care is a global priority. In the Metro Detroit area of Michigan, approximately 30% of PLWHIV are out of care. To re-engage lost-to-follow-up patients, Wayne Health Infectious Disease clinic launched an innovative Homecare program in 2017. In addition to home healthcare delivery, the program included links to community resources and quarterly community meetings. We aimed to evaluate Homecare's impact on participants' ability to stay engaged in HIV care and reach viral suppression. We included data from PLWHIV and their healthcare workers. METHODS: We used a convergent mixed-methods design, including first year program record review, semi-structured interviews, and a validated Likert scale questionnaire rating illness perception before and after Homecare. Interview data were collected from 15 PLWHIV in Metro Detroit and two healthcare workers responsible for program delivery. Semi-structured interviews focused on obstacles to clinic-based care, support networks, and illness perceptions. Interview data were transcribed and analyzed using a thematic approach. A fully coded analysis was used to create a conceptual framework of factors contributing to Homecare's success. Means in eight categories of the Brief Illness Perception (IPQ) were compared using paired T-tests. RESULTS: In the first year of Homecare, 28 of 34 participants (82%) became virally suppressed at least once. The program offered (1) social support and stigma reduction through strong relationships with healthcare workers, (2) removal of physical and resource barriers such as transportation, and (3) positive changes in illness perceptions. PLWHIV worked towards functional coping strategies, including improvements in emotional regulation, acceptance of their diagnosis, and more positive perspectives of control. Brief-IPQ showed significant changes in six domains before and after Homecare. CONCLUSION: Homecare offers an innovative system for successfully re-engaging and maintaining lost-to-follow-up PLWHIV in care. These findings have implications for HIV control efforts and could inform the development of future programs for difficult to reach populations.


Subject(s)
HIV Infections , Humans , Michigan , Follow-Up Studies , HIV Infections/therapy , Ambulatory Care Facilities , Coping Skills
2.
Clin Infect Dis ; 68(8): 1320-1326, 2019 04 08.
Article in English | MEDLINE | ID: mdl-30107568

ABSTRACT

BACKGROUND: Pneumocystis pneumonia (PCP) is associated with morbidity and mortality in solid organ transplant (SOT) recipients. In this case-control study, we determined the association between posttransplant PCP and 3 variables: cytomegalovirus (CMV) infection, allograft rejection, and prophylaxis. METHODS: Eight transplant centers participated. For each case (SOT recipient with PCP), 3-5 controls (SOT recipients without PCP) were included. Controls were matched to the cases based on transplant center, type of allograft, and date of transplantation (±6 months). RESULTS: We enrolled 53 cases and 209 controls. Transplant types included kidney (n = 198), heart (n = 30), liver (n = 15), kidney-pancreas (n = 14), and lung (n = 5). PCP occurred beyond 12 months after transplantation in 43 (81.1%) cases. Thirty-four cases (64.1%) required admission to the intensive care unit, and 28 (52.8%) had mechanical ventilation. Allograft failure occurred in 20 (37.7%) cases, and 14 (26.9%) died. No patient developed PCP prophylaxis breakthrough. The proportion of female sex (P = .009), kidney dysfunction (P = .001), cardiac diseases (P = .005), diabetes mellitus (P = .03), allograft rejection (P = .001), CMV infection (P = .001), and severe lymphopenia (P = .001) were significantly higher in cases. In the logistic regression model, CMV infection (adjusted odds ratio [aOR], 4.6 [95% confidence interval {CI}, 2.0-10.5]) and allograft rejection (aOR, 3.0 [95% CI, 1.5-6.1]) significantly increased the likelihood of PCP. CONCLUSIONS: PCP was mostly a late-onset disease occurring after complete course of prophylaxis, particularly among patients with CMV infection or allograft rejection. PCP is associated with significant allograft loss. Extended prophylaxis targeting recipients with allograft rejection or CMV infection may reduce the risk of PCP.


Subject(s)
Cytomegalovirus Infections/immunology , Graft Rejection/immunology , Pneumonia, Pneumocystis/immunology , Adult , Case-Control Studies , Female , Humans , Immunocompromised Host , Male , Middle Aged , Transplant Recipients , Transplantation, Homologous
3.
Int J Infect Dis ; 71: 1-3, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29550448

ABSTRACT

Mycoplasma hominis is part of the genitourinary flora in sexually active people and can cause disseminated infection in immunocompromised patients. We describe a rare case of an immunocompetent pregnant woman with simultaneous necrotizing HSV hepatitis and disseminated M. hominis infection. Detection of M. hominis and antimicrobial susceptibility testing of this fastidious organism in the clinical laboratory is discussed.


Subject(s)
Anti-Infective Agents/therapeutic use , Hepatitis/virology , Herpesvirus 2, Human/isolation & purification , Mycoplasma Infections/diagnosis , Mycoplasma hominis/isolation & purification , Pregnancy Complications, Infectious/diagnosis , Sexually Transmitted Diseases/diagnosis , Adult , Female , Hepatitis/drug therapy , Herpes Genitalis/immunology , Herpesvirus 2, Human/immunology , Humans , Microbial Sensitivity Tests , Mycoplasma Infections/drug therapy , Mycoplasma Infections/immunology , Pregnancy/immunology , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/immunology , Pregnancy Outcome , Pregnancy Trimester, Third , Sexually Transmitted Diseases/drug therapy , Sexually Transmitted Diseases/immunology , Treatment Outcome
4.
Am J Transplant ; 13(9): 2483-6, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23919410

ABSTRACT

Strongyloides stercoralis hyperinfection in an immunocompromised host has a high mortality rate but may initially present with nonspecific pulmonary and gastrointestinal symptoms. Donor-derived S. stercoralis by kidney transplantation is an uncommon diagnosis and difficult to prove. We report two renal allograft recipients on different immunosuppressive maintenance regimens that developed strongyloidiasis after transplantation from the same donor. Recipient 1 presented with a small bowel obstruction. Larvae were demonstrated on a duodenal biopsy and isolated from gastric, pulmonary, and stool samples. Serologic testing for S. stercoralis was negative at a referral laboratory but positive at the Centers for Disease Control. The patient's hospital course was complicated by a hyperinfection syndrome requiring subcutaneous ivermectin due to malabsorption. Recipient 1 survived but the allograft failed. Recipient 2 had larvae detected in stool samples after complaints of diarrhea and was treated. On retrospective testing for S. stercoralis, pretransplant serum collected from the donor and Recipient 1 was positive and negative, respectively. Donor-derived strongyloidiasis by renal transplantation is a preventable disease that may be affected by the immunosuppressive maintenance regimen. Subcutaneous ivermectin is an option in the setting of malabsorption. Finally, routine screening for S. stercoralis infection in donors from endemic areas may prevent future complications.


Subject(s)
Immunocompromised Host , Kidney Transplantation/adverse effects , Strongyloidiasis/transmission , Adult , Albendazole/therapeutic use , Animals , Ganciclovir/analogs & derivatives , Ganciclovir/therapeutic use , Humans , Ivermectin/administration & dosage , Ivermectin/therapeutic use , Malabsorption Syndromes , Male , Middle Aged , Strongyloides stercoralis , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Tissue Donors , Transplantation, Homologous/adverse effects , Valganciclovir
SELECTION OF CITATIONS
SEARCH DETAIL
...